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Edited by Masayuki MiyasakaAbstract We have cloned, expressed and characterized a novel
member of the human UDP-GalNAc:polypeptide N-acetylga-
lactosaminyltransferase (pp-GalNAc-T) family, pp-GalNAc-
T15. The pp-GalNAc-T15 transcript was ubiquitously expressed
in human tissues. Recombinant pp-GalNAc-T15 transferred N-
acetylgalactosamine (GalNAc) toward a panel of mucin-derived
peptide substrates in vitro. Although pp-GalNAc-T15 showed
signiﬁcantly less catalytic activity than pp-GalNAc-T2, T15
transferred up to seven GalNAcs to the Muc5AC peptide, while
T2 transferred up to ﬁve GalNAcs. These results clearly
indicated that pp-GalNAc-T15 is a novel member of the human
pp-GalNAc-T family with unique catalytic activity.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Mucin-type O-linked glycosylation is initiated by the addi-
tion of N-acetylgalactosamine (GalNAc) to serine or threonine
residues of the polypepide chain. This reaction is known to
be catalyzed by a family of UDP-GalNAc:polypeptide
N -acetylgalactosaminyltransferases (pp-GalNAc-Ts) (EC
2.4.1.41) [1], which transfer GalNAc from UDP-GalNAc to a
serine or threonine residue on the polypeptide acceptor. To
date, 14 distinct mammalian isoforms of this gene family (T1–
T14) [1–17] have been identiﬁed and functionally character-
ized. These isoforms have been shown to have unique acceptor
substrate speciﬁcities as well as tissue-speciﬁc expression pat-
terns; several isoforms are expressed in various tissues and
catalyze a broad spectrum of substrates (pp-GalNAc-T1, T2),
whereas the other isoforms are more restricted in expression
and/or in substrate preference (pp-GalNAc-T3, T4, T7, T9,
T11 and T13). The diﬀerences in kinetic properties, substrate
speciﬁcities, and expression patterns of pp-GalNAc-Ts are
presumably involved in a hierarchical order of the mucin-type
O-glycosylation processing and govern O-glycan attachment
sites and density on peptide backbones in vivo. Although it is
still hard to deﬁne the in vivo catalytic speciﬁcity and biolog-
ical function of an individual GalNAc-T isoform, a few in vivo
studies have conﬁrmed the in vitro characterization of catalytic
activity, mainly characteristic sequence motifs of acceptor
substrates [18]. Thus, to understand how O-glycosylation is
initiated and regulated in a given tissue or cell type, the rep-
ertoire and catalytic speciﬁcity of pp-GalNAc-Ts in that cell
background have to be deﬁned.
In the present study, we report the cloning and character-
ization of pp-GalNAc-T15, a novel member of this GalNAc-
transferase family. For the characterization, we compared the
catalytic speciﬁcity of pp-GalNAc-T15 with that of T2, and
found it to be totally diﬀerent.2. Materials and methods
2.1. Cloning of pp-GlaNAc-T15 cDNA
A BLAST search of expressed sequence tag (EST) databases iden-
tiﬁed three cDNAs (GenBankTM Accession Nos.: BG699346,
BG714178 and BG715977) as homologues to the open reading frameblished by Elsevier B.V. All rights reserved.
Table 1
Acceptor peptide speciﬁcities of puriﬁed recombinant pp-GalNAc-T15 and -T2
Acceptor peptide Amino acid sequence GalNAc-T15 (U/lg) GalNAc-T2 (U/lg)
Muc1a AHGVTSAPDTR 0.023 0.24
Muc2 PTTTPITTTTTVTPTPTPTGTQT 0.008 7.94
Muc5AC GTTPSPVPTTSTTSAk 0.0126 8.37
Muc13 ANTPSFPTATSPAPPI 0.012 2.98
EA2 PTTDSTTPAPTT 0.006 3.06
Relative activity determined in reactions containing 200 lM peptide substrate and puriﬁed GalNAc-T15 and -T2.
18 L. Cheng et al. / FEBS Letters 566 (2004) 17–24(ORF) of human pp-GalNAc-T7 (AJ002744). By searching the human
genomic DNA database, we found a genomic sequence (NT005927)
that contained a putative initial codon and a transmembrane domain
of this putative gene. A full-length ORF of a novel polypeptide Gal-
NAc transferase was identiﬁed by database gene walking and depos-
ited into GenBank with the Accession No. AB078149. The cDNA
encoding the full-length ORF was obtained by polymerase chain re-
action (PCR) using the ExpandTM High Fidelity PCR system (Roche),
the Marathon-readyTM cDNA of human cerebellum (Clontech) as a
template, and the primers, 50-GGGGACAAGTTTGTACAAAA-
AAGCAGGCTTCATGCTCCTAAGGAAGCGATACAGGCAC-30
(forward) and 50-GGGGACCACTTTGTACAAGAAAGCTGGGT-
CCTCATCGTTCATCCACAGCATTGATCT-30 (reverse). These
primers have an attB1 or an attB2 overhang to create recombination
sites. The ampliﬁed fragment was subcloned into the vector
pDONR201TM using the BP CLONASE Enzyme Mix (Invitrogen).
The sequences of subcloned cDNA were determined using a DYE-
namicTM DNA Sequencing Kit (Amersham Pharmacia Biotech).
2.2. Quantitative analysis of the pp-GalNAc-T15 transcripts in human
tissues by real-time PCR
Real-time PCR was carried out using the TaqMan Universal PCR
Master Mix (Applied Biosystems), Marathon-Ready cDNAs of
various human tissues (Clontech), the forward primer (50-GGATG-
TGCTCGTCTTCATGGA-30), the reverse primer (50-GATACCAC-
TCGGCTCCTGTCA-30), and the probe (50-CTGGAGCCCCTCCT-
CAGCAGAATAGC-30). Standard curves were generated by methods
described previously [19]. PCR products were continuously measured
with the ABI PRISM 7700 Sequence Detection System (Applied Bio-
systems). The relative amount of pp-GalNAc-T15 transcript was nor-
malized to the amount of human glyceraldehyde-3-phosphate
dehydrogenase transcript in each cDNA.
2.3. Production and puriﬁcation of recombinant pp-GalNAc-T15 protein
with FLAG peptide tag
The cDNA fragment encoding the putative catalytic domain of pp-
GalNAc-T15 (amino acids 45–639) was ampliﬁed by PCR using
the primers, 50-GGGGACAAGTTTGTACAAAAAAGCAGGCTT-
CGCCAGGTACCGCCTGGACTTTGGGG-30 (forward) and
50-GGGGACCACTTTGTACAAGAAAGCTGGGTCCTCATCGT-
TCATCCACAGCATTGATCT-30 (reverse). The ampliﬁed cDNA
fragment was cloned into pDONR201TM and subcloned into the ex-
pression vector pFBIF using the LR CLONASE Enzyme Mix (Invit-
rogen) [13,19]. The pFBIF–pp-GalNAc-T15 truncated construct was
tranformed into DH10BAC competent cells (Invitrogen) to generate
bacmid DNA. The bacmid was introduced into Sf21 cells (Pharmin-
gen) to yield conditioned medium containing recombinant pp-Gal-
NAc-T15 protein. The secreted recombinant protein was puriﬁed using
anti-FLAG M1 antibody-conjugated resin (Sigma). The puriﬁed pro-
tein was fractionated by 10% SDS–PAGE, and analyzed by Western
blotting using anti-FLAG M2 (Sigma) and the enhanced chemilumi-
nescence-plus (ECLþ) Western Blot Detection Kit (Amersham Bio-
sciences). The relative concentration of the puriﬁed protein was
estimated using the FLAG-tagged bacterial alkaline phosphatase
(Sigma) as a standard.
The soluble form of human pp-GalNAc-T2, containing amino acid
residues 52–571 [2], was also generated, puriﬁed and quantiﬁed by the
same methods as for pp-GalNAc-T15.
2.4. Polypeptide GalNAc-transferase assays
The standard enzyme reaction mixture (ﬁnal volume, 20 ll) con-
sisted of 25 mM Tris–HCl (pH 7.4), 10 mM MnCl2, 0.2% Triton X-100, 1 mM UDP-GalNAc (Sigma), 5 mM 2-mercaptoethanol, 0.005–2
mM acceptor peptides labeled with 5-carboxyﬂuorescein succinimidyl
ester (FAM), and an adequate amount of puriﬁed pp-GalNAc-Ts.
Reactions were performed at 37 C for various periods and were ter-
minated by boiling. FAM-labeled peptide substrates: Muc1a, Muc2,
Muc5AC, Muc13 and EA2 [20–24] (see Table 1 for structure), which
were derived from the tandem repeats of corresponding mucins, were
purchased from Sawady Co. Ltd (Tokyo, Japan). The reaction prod-
ucts were evaluated by high-performance liquid chromatography
(HPLC) on a C18 reverse column (Water 5C18-AR, 4.6 250 mm) as
previously described [25].
For the initial velocity assay of pp-GalNAc-Ts with a variety of
substrate peptides, the amount of substrate consumed was limited to
less than 10% of the total. The relative activity of pp-GalNAc-Ts with
each substrate peptide was presented as units per micrograms. One unit
of enzyme is deﬁned as the amount of enzyme that transfers 1 nmol of
GalNAc in 1 min using the standard reaction mixture. The GalNAc-
transferase assay, to determine the Km for the acceptor substrate
Muc1a, was modiﬁed to include 1 mM UDP-GalNAc with Muc1a at
concentrations from 0.005 to 2 mM. Assays to determine the Km for
UDP-GalNAc were performed with the saturating concentration of
Muc1a peptide (pp-GalNAc-T15, 1 mM Muc1a; pp-GalNAc-T2, 500
lM Muc1a). Assays were performed in duplicate or quadruplicate.
2.5. Separation of enzyme reaction products
The glycosylated peptides were isolated by HPLC. As a standard
separation, the reaction products were eluted with 13% solvent B
(0.05% triﬂuoroacetic acid (TFA) in 70% 2-propanol in acetonitrile) in
solvent A (0.05% TFA in water) at a ﬂow rate of 1 ml/min for 60 min.
Eluates were monitored by the ﬂuorescence intensity at 520 nm (ex-
citation: 492 nm).
2.6. Identiﬁcation of reaction products by matrix-assisted laser
desorption/ionization time-of-ﬂight (MALDI-TOF) spectrometry
and peptide sequencing
The isolated fractions were dried, redissolved in distilled water,
mixed with the same amount of matrix solution (a-cyano-4-hydroxy-
cinnamic acid, saturated in 30% acetonitrile containing 0.1% TFA),
and subjected to MALDI-TOF mass spectrometry using REFLEXTM
IV (Bruker Daltonics) in the negative ion mode. The method was de-
scribed in our previous report [25].
To identify the positions of GalNAc-attached residues, amino acid
sequencing of glycopeptides by Edman degradation was performed
with a peptide sequencer (PPSQ-23A, Shimadzu). With this sequencing
system, a phenylthiohydantoin (PTH) derivative of GalNAc-attached
Thr (Calbiochem, Darmstdt, Germany) was identiﬁed as a pair of
peaks eluted at 3.07 and 3.25 min, which were close to the DTT peak,
and that of GalNAc-attached Ser was identiﬁed as a peak at 2.96 min,
which overlapped the PTH-Glu peak.3. Results
3.1. cDNA cloning of pp-GalNAc-T15
The pp-GalNAc-T15 gene was identiﬁed as a putative novel
pp-GalNAc-T gene by searching the EST database with the
human pp-GalNAc-T7 gene as a query, and the cDNA was
cloned as described in Section 2. The nucleotide and deduced
amino acid sequences of pp-GalNAc-T15 are shown in
Fig. 1A, and an alignment of the amino acid sequences of 13
Fig. 1. (A) Nucleotide and predicted amino acid sequences of pp-GalNAc-T15. Numbering of the cDNA begins with the initiation codon. The
predicted amino acid sequence is presented under the putative nucleotide coding sequence. The triangle represents the starting position of the
truncated form. The predicted transmembrane domain is underlined with a single solid line. (B) ClustalW alignment for comparison of pp-GalNAc-
T15 with the other pp-GalNAc-Ts. The putative transmembrane domains are underlined. Three motifs, GT1, Gal/GalNAc transferase and lectin-
like, are indicated above the sequences. The amino acids that are identical among all proteins are shown by asterisks, while conserved amino acids are
shown by dots.
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20 L. Cheng et al. / FEBS Letters 566 (2004) 17–24pp-GalNAc-Ts generated using ClustalW is shown in Fig. 1B.
The cDNA encoding pp-GalNAc-T15 contains an ORF of
1917 bp encoding a 639-amino acid type II membrane protein,
comprising an N-terminal cytoplasmic domain, a transmem-
brane domain, a putative stem region and a catalytic region
containing the conserved GT1 and Gal/GalNAc-T motifs and
a lectin-like domain. The pp-GalNAc-T15 gene was localized in
a draft genome sequence that was mapped to human chro-
mosome 3 at p25. The ORF of pp-GalNAc-T15 contained at
least 10 exons separated by 9 introns.
3.2. Distribution of pp-GalNAc-T15 transcripts in human
tissues
The expression levels of the pp-GalNAc-T15 transcripts in
various human tissues were examined by the quantitative real-
time PCR method. The pp-GalNAc-T15 gene was expressed in
most tissues examined although at diﬀerent levels (Fig. 2).
High levels of expression were found in small intestine, pla-
centa, spleen, cerebral cortex, and ovary, while intermediate
levels were observed in uterus, mammary gland, stomach,
cerebellum, and whole brain. The expression levels were
undetectable in leukocyte and very low in the other tissues
tested.
3.3. Analysis of pp-GalNAc-T15 catalytic activity
Recombinant pp-GalNAc-T15 and -T2 were generated in
culture media of Sf21 cells that were infected with baculo vi-0
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Fig. 2. Quantitative analysis of pp-GalNAc-T15 transcripts in various huma
GAPDH were generated by serial dilution of each plasmid DNA. The express
GAPDH transcript, which was measured in the same cDNAs. Values were ex
were obtained from triplicate experiments and indicated as means SD.
Table 2
Kinetic constants of puriﬁed recombinant GalNAc-transferases
Substrate sequence GalNAc-T15
Km (mM) Vmax (nmol/m
Acceptor substrate
Mucla AHGVVTSAPDTR 0.910 0.062
Donor substrate
UDP-GalNAc 0.016 0.087ruses carrying secretion from constructs of T15 and T2. These
recombinant enzymes were puriﬁed to near homogeneity by
the method described in Section 2 and were quantiﬁed by
SDS–PAGE with FLAG-BAP as standard. T2 was chosen as a
control for T15 because T2 sequence was well characterized
and more homologous to T15 than T7. The acceptor substrate
speciﬁcities of pp-GalNAc-T15 and -T2 presented in Table 1
were obtained with a variety of peptides. pp-GalNAc-T15
showed the strongest activity toward the Muc1a peptide,
however, T15 showed considerably less catalytic eﬃciency than
T2 that is arguably the most robust enzyme among pp-Gal-
NAc-Ts.
Furthermore, detailed comparative analysis of the catalytic
activities of pp-GalNAc-T15 and -T2 was performed for the
Muc1a peptide, as well as the sugar donor UDP-GalNAc. The
kinetic constants of GalNAc-T15 and -T2 are summarized in
Table 2. Puriﬁed pp-GalNAc-T15 exhibited a Km value of
0.016 mM for UDP-GalNAc and a Km value of 0.910 mM for
Muc1a. These values are lower than those detected for T2 (Km
of 0.081 mM for UDP-GalNAc and 0.450 mM for the Muc1a
peptide substrate).
To further analyze catalytic speciﬁcity, pp-GalNAc-T15 and
-T2 were incubated with Muc5AC peptide and analyzed by
HPLC. Muc5AC peptide is a substrate broadly used for testing
pp-GalNAc-T activities. As shown in Figs. 3A and 4A, the
substrate peak (S) was gradually consumed and the product
peaks (P) appeared with the extended incubation time. TheLu
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ion level of the pp-GalNAc-T15 transcript was normalized to that of the
pressed as copy numbers of the target gene in 1 lg of total RNA. Data
GalNAc-T2
in/lg) Km (mM) Vmax (nmol/min/lg)
0.450 0.404
0.081 0.0.384
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Fig. 4. MALDI-TOF-MS analysis of reaction products of pp-GalNAc-
T15 (A) and -T2 (B). Each peak of the reaction products (P1–P11 and
P10–P60) and substrate (S) in Figs. 3A and B was fractionated by
HPLC and subjected to MALDI-TOF-MS analysis.
Retention time (min)
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Fig. 3. HPLC analysis of the in vitro O-glycosylation of the Muc5AC
peptide by pp-GalNAc-T15 and -T2. (A,B) The elution proﬁles of the
Muc5Ac peptide glycosylated by pp-GalNAc-T15 and -T2, respec-
tively. Peak S corresponds to the original substrate, Muc5AC peptide.
Peaks P1–P11 correspond to the products generated by pp-GalNAc-
T15. Peaks P10–P60 correspond to the products generated by pp-Gal-
NAc-T2. The incubation time is indicated on the right of the panels.
L. Cheng et al. / FEBS Letters 566 (2004) 17–24 21HPLC patterns of pp-GalNAc-T15 and -T2 no longer changed
even after a prolonged incubation of 24 h or the addition of
fresh enzymes and UDP-GalNAc after 24 h incubation. This
indicated that the peaks at 36 or 48 h are the ﬁnal products of
pp-GalNAc-T15 and -T2, respectively. The elution proﬁles of
reaction products on HPLC generated by pp-GalNAc-T15 and
-T2 were totally diﬀerent. At least 11 product peaks, named
P1–P11, were generated by pp-GalNAc-T15, and the major
peaks were P2 and P6 (Fig. 3A). Whereas, pp-GalNAc-T2
generated 6 product peaks, named P10–P60, with P50, the major
product (Fig. 3B). The retention time of the initial product
peak P10 (38.2 min) was apparently diﬀerent from that of P1
(31.5 min). These results demonstrated that pp-GalNAc-T15
and -T2 exhibited diﬀerent substrate speciﬁcities.3.4. Determination of the number of GalNAc residues attached
to the substrate peptide by MS
To identify the number of GalNAc residues attached to the
Thr/Ser of the substrate peptide, Muc5AC, each HPLC peak of
reaction products generated by GalNAc-T15 and -T2 was
fractionated, and then subjected to MALDI-TOF-MS analysis.
MS spectra of all peaks for pp-GalNAc-T15 and -T2 are pre-
sented in Figs. 4A and B, respectively. [H] ion was observed as
the major ion from all derivatives. From the MS analysis, the
molecular weight of Muc5AC and GalNAc is 1890.2 and 203.2,
22 L. Cheng et al. / FEBS Letters 566 (2004) 17–24respectively. P1 had a molecular mass of 2093.4, which showed
that the fraction corresponded to Muc5AC bearing one gly-
cosylated residue. P2 had a molecular mass of 2296.7, which
showed that the fraction contained two GalNAc residues.
Thus, P3, P4 and P5 are identiﬁed as tri-GalNAc Muc5AC
glycopeptides, and the results are interpreted as P6 and P7 (four
GalNAcs), P8 and P9 (ﬁve GalNAcs), and P10 (six GalNAcs),
and ﬁnally, P11 (seven GalNAcs). As shown in Fig. 4B, pp-
GalNAc-T2 transferred a maximum number of ﬁve GalNAcs
to the Muc5AC peptide, P10 (one GalNAc), P20 and P30 (two
GalNAcs), P40 (three GalNAcs), P50 (4GalNAcs) and ﬁnally
P60 (ﬁve GalNAcs). Thus, pp-GalNAc-T15 and -T2 diﬀered in
the maximum number of GalNAcs they incorporated into the
Muc5AC peptide.3.5. Identiﬁcation of the position of GalNAc attached to
Muc5AC by peptide sequencing analysis
The glycosylated peptide in each peak in Figs. 3A and B was
isolated by HPLC and subjected to peptide sequencing to de-
termine the sites of GalNAc attachment to the Muc5AC
peptide. The pathways of O-glycosylation by pp-GalNAc-T15
and -T2 are schematically presented in Figs. 5A and B, re-
spectively. As shown in Fig. 5A, the ﬁrst site of incorporation
by pp-GalNAc-T15 was Thr-3 (P1), then Thr-2 (P2). P3 and
P5 were products of P2 generated by the addition of GalNAc
to Thr-9 and Thr-12, respectively. It is clear that P2 is not the
precursor of P4, which consisted of a peptide glycosylated at
Thr-3, Ser-11 and Thr-13. P3 was further glycosylated at Ser-
11 to produce P6 followed by Thr-10 to yield P8. P7 was fromP1
GTT*PSPVPTTSTTSA
P3
GT*T*PSPVPT*TSTTSA
P2
GT*T*PSPVPTTSTTSA
P5
GT*T*PSPVPTTST*TSA
P4
GTT*PSPVPTTS * TT*SA
P6
GT*T*PSPVPT*TS*TTSA
P8
GT*T*PSPVPT*T*S*TTSA
P7
GT*T*PSPVPTTST*T*SA
P9
GT*T*PSPVPTTS*T*T*SA
P10
GT*T*PSPVPTT*S*T*T*SA
P11
GT*T*PSPVPT*T*S*T*T*SA
P1’
GTTPSPVPT*TSTTSA
P3’
GTTPS*PVPT*TSTTSA
P2’
GTT*PSPVPT*TSTTSA
P5’
GTT*PS*PVPT*TSTT*SA
P4’
GTT*PS*PVPT*TSTTSA
P6’
GTT*PS*PVPT*TS*TT*SA
A
B
Fig. 5. Schematic representation of the predicted pathways of GalNAc
incorporation into Muc5AC peptide by pp-GalNAc-T15 (A) and -T2
(B). The pathways of GalNAc incorporation into Muc5AC peptide by
pp-GalNAc-T15 and -T2 were predicted based on the analysis of MS
and peptide sequencing. Amino acids with asterisks are the residues to
which the attachment of GalNAc was conﬁrmed.P5 obtained by the addition of GalNAc to Thr-13. P7 was then
glycosylated stepwise to yield P11 according to the following
order, P9 (Ser-11), P10 (Thr-10) and P11 (Thr-9). Thus, the
ﬁnal product generated by pp-GalNAc-T15, P11, was gly-
cosylated at seven sites in the Muc5AC peptide, Thr-2, Thr-3,
Thr-9, Thr-10, Ser-11, Thr-12 and Thr-13.
As shown in Fig. 5B, pp-GalNAc-T2 ﬁrstly transferred a
GalNAc residue to Thr-9 (P10), with the second site of incor-
poration by Thr-3 (P20) or Ser-5 (P30). Then, P20 and P30 were
further glycosylated to produce P40 by the addition of GalNAc
to Ser-5 and Thr-3, respectively. P50, having four GalNAcs at
Thr-3, Ser-5, Thr-9 and Thr-13, was generated by the addition
of GalNAc to Thr-13 of P40. Finally, P60 was formed by the
addition of GalNAc to Ser-11 of P50. Thus, the ﬁnal product of
pp-GalNAc-T2, P60 had GalNAcs at ﬁve positions, Thr-3, Ser-
5, Thr-9, Ser-11 and Thr-13. These results clearly indicated
diﬀerences in site-speciﬁc and order-speciﬁc GalNAc incor-
poration by pp-GalNAc-T15 and by T2.4. Discussion
The initiation of mucin-type O-glycosylation is catalyzed by
the action of a family of pp-GalNAc-Ts. Studies over the past
decade have found that pp-GalNAc-Ts display diﬀerences in
both substrate speciﬁcity and tissue distribution. In the present
study, we cloned and characterized a novel isoform of the
GalNAc-Ts, pp-GalNAc-T15.
Mammalian pp-GalNAc-T transcripts vary in their level and
distribution among human tissues. It was reported that pp-
GalNAc-T1, -T2, -T4, -T7, -T8, -T10, -T12 and -T14 were
expressed ubiquitously [2,5,9,10,13,15,17], whereas pp-Gal-
NAc-T3, -T6, -T9, -T11 and -T13 had more restricted distri-
butions [3,8,11,14,16]. By real-time PCR analysis, the
pp-GalNAc-T15 transcript was broadly expressed in various
tissues, although the highest level of expression was found in
the small intestine, nervous system and female reproductive
system. These tissues are where the Muc5AC gene is also
highly expressed [22], suggesting that Muc5AC is a potential
substrate for T15.
In addition to diﬀerential tissue distribution, distinct, al-
though partly overlapping, substrate speciﬁcities of pp-Gal-
NAc-Ts are considered to contribute to the O-glycosylation
pattern in certain tissues and cells. In previous studies, apo-
proteins, peptidic fragments and synthetic peptides have been
used to evaluate the O-glycosylation reactions in vitro in an
attempt to deﬁne the acceptor substrate speciﬁcities for the
diﬀerent pp-GalNAc-Ts [26]. In the present study, we used
synthetic peptides as acceptor substrates to compare the sub-
strate speciﬁcities of puriﬁed recombinant pp-GalNAc-T15
and -T2. Both enzymes showed GalNAc-transferase activities
toward a panel of peptide substrates listed in Table 1, but the
initial velocities of pp-GalNAc-T15 were considerably lower
than those of pp-GalNAc-T2 with all substrates examined.
Even though pp-GalNAc-T15 showed the best and T2 showed
the poorest activity with Muc1a, T15 showed clearly less ac-
tivity with Muc1a than T2. The catalytic activity of pp-Gal-
NAc-T2 was similar to that in previous reports [25,27]. Further
detailed analysis of the activity revealed that pp-GalNAc-T15
had a lower Km with Muc1a and UDP-GalNAc than
pp-GalNAc-T2 but also had a lower Vmax. These results
demonstrated that pp-GalNAc-T15 had weaker catalytic
L. Cheng et al. / FEBS Letters 566 (2004) 17–24 23activity toward all acceptor substrates examined than pp-
GalNAc-T2. It was reported that pp-GalNAc-T2 showed a Km
value of 2.13 mM with the Muc1a peptide [27], which was not
consistent with the Km value obtained in our experiment. We
considered that the diﬀerent expression and assay system might
result in the diﬀerence.
The in vitro transferase analysis has shown that the sites of
GalNAc incorporation in peptide substrates as well as the
order of the incorporation diﬀer markedly with each pp-Gal-
NAc-T isoform even when the same sites are glycosylated [27–
29]. In the present study, we found that the pp-GalNAc-T15
and the Muc5AC genes have similar expression patterns.
Muc5AC peptide (GTTPSPVPTTSTTSA), derived from hu-
man Muc5AC, has been considered an excellent substrate for
evaluating the substrate speciﬁcity of GalNAc-Ts [22]. Thus, to
gain further insight into the speciﬁcity of pp-GalNAc-T15, the
sites and order of GalNAc incorporation into Muc5AC by pp-
GalNAc-T15 and -T2 were analyzed.
As summarized in Figs. 5A and B, the sites and order of
incorporation on Muc5AC were totally diﬀerent between pp-
GalNAc-T15 and -T2. The initial site of incorporation in the
Muc5AC peptide by pp-GalNAc-T15 was Thr-3, followed by
Thr-2, or Thr-13/Ser-11. The ﬁnal product by T15 was gly-
cosylated at seven sites in Muc5AC (GT*T*PSVPT*T*
S*T*T*SA, GalNAc attachment sites marked by asterisks) by
the order indicated in Fig. 5A. In contrast, the initial site of
attachment to Muc5AC by pp-GalNAc-T2 was Thr-9, then
Thr-3 or Thr-5, and the ﬁnal product generated by pp-Gal-
NAc-T2 was glycosylated at ﬁve sites (GTT*PS*VPT*
TS*TT*SA). There is substantial evidence that the sequence
motifs surrounding Ser/Thr residues play crucial roles in
transfer of GalNAc by pp-GalNAc-Ts. The proline residues
located at +3, +1 and /or )1 relative to the glycosylation site
have positive eﬀects, and the sequence motif XTPXP is con-
sidered to well serve as a signal for mucin-type O-glycosyla-
tion [30–35]. The hydroxy group of Thr-3, Ser-5, Thr-9, and
Thr-13 in Muc5AC peptide matched such rules. We observed
that the initial glycosylation site by pp-GalNAc-T15 and the
most glycosylation sites by T2 were consistent with proline
rule.
However, the site speciﬁcity of pp-GalNAc-T15 appears not
to be merely governed by the peptide sequence around putative
target sites. The initial GalNAc-attachment to Muc5AC pep-
tide may also considerably inﬂuence subsequent glycosylation
events through, presumably, conformation change in Muc5AC
peptide. In the major glycosylation pathway by pp-GalNAc-
T15, Thr-3 of the Thr-2/Thr-3 doublet was ﬁrst glycosylated,
and then, Thr-2 was glycosylated. After the Thr-12 was gly-
cosylated, the vicinal Thr- or Ser- of GalNAc-attached sites
was glycosylated one by one. This phenomenon is consistent
with the activity of pp-GalNAc-T3 and -T4, which preferen-
tially transfer GalNAc to the consecutive Thr residues in a
synthetic peptide (PTTTPITTTTK) derived from Muc2 [36].
In contrast, pp-GalNAc-T2 could only transfer GalNAc to
one of the two consecutive Thr- or Ser-residues, and the vicinal
Thr- or Ser-residues of GalNAc-attached sites were not gly-
cosylated by T2. This phenomenon resulted in that less Gal-
NAcs were transferred onto Muc5AC peptide by T2 than T15.
We presume that this critical diﬀerence between pp-GalNAc-
T2 and T15 is generated by distinct acceptor recognitions by
these two enzymes. The site preferences of pp-GalNAc-T2 on
Muc5AC peptide were consistent with previous results usingMuc2 peptide and IgA1 and hinge peptide as substrates
[25,36].
Among the glycosylated products generated by pp-GalNAc-
T15, P8 and P4 may be dead-end products of the reaction.
They might be precursors of P10 and P9, respectively, how-
ever, no intermediates were found. P1–P4 also lacked inter-
mediates. These intermediates, if exist, exist as small peaks that
could not be fractionated, and such products were immediately
further glycosylated. If P8 and/or P4 are dead-end products, it
means that pp-GalNAc-T15 could not transfer GalNAcs
to certain sites that are located next to GalNAc-attached res-
idues.
We observed that pp-GalNAc-T15 transferred up to seven
GalNAc residues to the Muc5AC peptide, a number signiﬁ-
cantly higher than that by pp-GalNAc-T2 (ﬁve GalNAcs) or
any single established isoform. It was reported that three
major isoforms of pp-GalNAc-Ts (murine T1, T2 and T3)
transferred a maximum of three GalNAc residues into Mu-
c5AC peptide [37], and only a pool of enzymes (the micro-
somal preparation of human gastric mucosa) cause all 6
threonine residues in the Muc5AC peptide to be fully gly-
cosylated [38]. Thus, we presume that pp-GalNAc-T15 plays
signiﬁcant roles in in vivo O-glycosylation of Muc5AC and
other substrates, especially in ﬁlling in vicinal Thr/Ser residues
incorporation with other pp-GalNAc-Ts.Acknowledgements: This work was performed as a part of the R&D
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